Lupin’s Post

Read an insightful opinion piece by Nilesh Gupta, Managing Director, Lupin in the latest issue of Business Today magazine on the roadmap with actionable steps and strategies for a healthier India in the coming years. https://lnkd.in/dhVrPj3c #Lupin #Pharmaceuticals #Leader #InsightfulThoughts #WeAreLupin #ProudLupinytt

Digital Health is a way to reach and provide care to maximum indians.

#PrescribingTrustDeliveringQuality: Sh. Sandeep Jain, Jt. Managing Director of Akums, on our unwavering commitment to superior quality. We live and breathe the vision of excellence every day. To learn more about us, visit: https://lnkd.in/gHFaHCyd #Akums #AkumsCares #PharmaIndustry #contractmanufacturing #pharmaceuticals #akumsstrength #innovation #manufacturing #quality #pharmaceuticalindustry

#PrescribingTrustDeliveringQuality: Sh. Sandeep Jain, Jt. Managing Director of Akums, on our unwavering commitment to superior quality. We live and breathe the vision of excellence every day. To learn more about us, visit: https://lnkd.in/dH5te3ac #Akums #AkumsCares #PharmaIndustry #contractmanufacturing #pharmaceuticals #akumsstrength #innovation #manufacturing #quality #pharmaceuticalindustry

As we team up with Planisware for an unforgettable collaboration! Join us on September 14th, between 11:00 am to 12:00 pm, as we proudly welcome Arnaud Goumain and Kevin Duhaut to the WHYSummits stage. We invite you to join us for an engaging dive into Strategic Pharmaceutical Project Management. #whysummits #ppmmumbai #portfoliomanagement #partnerships #healthcarestrategy #pharmaceutical #indianpharma #portfolio #projectmanagement

Sole sourcing is risky, but could it be bad for our national health? https://lnkd.in/efeQwsTv The June Art of Supply interview features Victor Suarez, Lead Vaccine Program Manager for Moderna’s COVID-19 vaccine during Operation Warp Speed (2020-2021) and Founder and Principal Growth Partner at Blu Zone Bioscience & Supply Chain Solutions, LLC. He shares his frank point of view on why today’s pharmaceutical supply chains are under strain: - Why facilitating the market entry of generic drugs in 1984 led to the scarcity we face today  - The surprising challenge (and importance) of defining “Made in the U.S.A.” - The solution he sees as the most likely to succeed, especially given the reasonable investment associated with it #supplychain #pharmaceuticals #drugshortages Art of Procurement Buyers Meeting Point

The link between America's drug shortage crisis and supply chain challenges America's drug shortage crisis is intricately linked to the complexities within the pharmaceutical supply chain. While the intuitive solution to this crisis might seem to be a straightforward increase in domestic manufacturing, Allen Jacques from Kinaxis a leader in supply chain management platforms, has provided insight into why this approach might not be the silver bullet many hope for. "America's drug shortage crisis is deeply entangled with the pharmaceutical supply chain's complexities," Jacques explained. Additionally, some companies prioritise the production of patent-protected drugs over generics, exacerbating shortages in critical medications. "It's worth noting that while shortages for high-margin patent-protected drugs are relatively rare, exceptions like Wegovy and Zepbound exist, presenting unique challenges. However, these instances differ from the broader trends observed in the generic drug market. Despite the profitability of patent-protected drugs, supply chain resilience remains critical across all pharmaceutical industry segments". To learn more, read the article: https://ow.ly/2RTu50Rc8Nj #DrugShortageCrisis #SupplyChainChallenges #PharmaceuticalSupplyChain #SupplyChainManagement #PharmaceuticalIndustry #DrugShortages #GenericDrugs #SupplyChainResilience #PharmaInsights #HealthcareSupplyChain

Otsuka Pharmaceutical India Pvt. Ltd. (OPI) conducted DISHA 4.0 - The Annual Strategy Meet 2023. DISHA is an effective platform to review the Hits and Misses of the year gone by and form strategies for the next year, to pave the way towards the direction of growth and wellbeing. Here are a few glimpses of the event... #OPI #Otsuka #pharmaceutical #India #strategy #businessdevelopment #growth #quality #manufacturing #review #businessgoals

“Exploring the Cipla Case Study: Insights from Dr. V. S. Pai’s Research” 🌟 In this engaging presentation, I delve into the fascinating world of Cipla, a leading generics manufacturer. Dr. Pai’s meticulous analysis sheds light on the company’s journey, challenges, and strategic decisions. Join me as we unravel the complexities of the pharmaceutical industry and discover how Cipla navigated the generics versus drug discovery landscape. 🚀🔍 #Cipla #CaseStudy #Pharmaceuticals #ResearchInsights #kim #pgdm

Pharma Outsourcing Trends from an Informa Markets Perspective: https://lnkd.in/eEeDsejM? The looming expiry of patents are also driving pharmaceutical companies to invest in drug pipelines. This demand thus forces pharmaceutical outsourcing vendors to search for ways to remain competitive. The priority for contract organisations is still speed and cost – emphasis is placed on flexible operations, increased efficiency with continuous manufacturing and digitalization of processes, supply chain resiliency, and end-to-end ‘one-stop shop’ services to cover the whole value chain for their customers. Because of supply chain disruptions of the last few years, pharmaceutical companies are now reserving and even double-booking considerable partnerships with contract manufacturers. AstraZeneca, Moderna, and Pfizer have all penned partnerships with multiple CDMOs including Lonza, Catalent, and Emergent Biosolutions. CDMOs are now adjusting their business models through internal investments and strategic M&A initiatives to keep up with demand for expanded services from multiple customers. Plants are expanding – Cambrex and Samsung Biologics have all announced or started major expansions of manufacturing plants. Thanks to Adam Andersen Vivian Xie Informa Markets #cdmo #pharmamanufacturing #cmoinsights #biopharmaceuticals